Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 8/2015

01-08-2015 | Pediatric Type 2 Diabetes (PS Zeitler, Section Editor)

Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics

Authors: Pornpoj Pramyothin, Lalita Khaodhiar

Published in: Current Diabetes Reports | Issue 8/2015

Login to get access

Abstract

Youth receiving treatment with antipsychotics are particularly susceptible to weight gain, type 2 diabetes (T2D), and associated metabolic disorders, which is directly associated with excess morbidity and mortality in this vulnerable population. The risk of T2D is 2- to 3-fold that of the general population, starts early in the course of treatment, and reflects the effects of weight gain in conjunction with direct effects of antipsychotics on the hypothalamus, pancreatic beta cells, and insulin-sensitive peripheral tissues. Close monitoring with early intervention through lifestyle intervention, switching away from antipsychotics with deleterious metabolic effects, and adjunctive treatment with metformin are modalities available to mitigate weight gain and improve cardiometabolic health in these patients. Despite rapidly advancing knowledge in the field, patient’s access to metabolic screening and quality care remains limited. Efforts must be made to broaden reach of early cardiometabolic intervention among these patients in order to avert serious cardiovascular disease burden in the future.
Literature
1.
Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry: J Mental Sci. 2010;196(2):116–21.CrossRef
2.
Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004;47:S64–6.PubMedCrossRef
3.
Casagrande SS, Anderson CA, Dalcin A, Appel LJ, Jerome GJ, Dickerson FB, et al. Dietary intake of adults with serious mental illness. Psychiatric Rehabil J. 2011;35(2):137–40.CrossRef
4.
Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry. 2009;31(6):555–63.PubMedCentralPubMedCrossRef
5.
Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA. 2014;311(2):172–82.PubMedCrossRef
6.
Dickey B, Normand SL, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002;53(7):861–7.PubMedCrossRef
7.
Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res. 2010;123(2–3):234–43.PubMedCrossRef
8.
Kilbourne AM, McCarthy JF, Post EP, Welsh D, Pincus HA, Bauer MS, et al. Access to and satisfaction with care comparing patients with and without serious mental illness. Int J Psychiatry Med. 2006;36(4):383–99.PubMedCrossRef
9.
10.
Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247–56.PubMedCrossRef
11.
Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacol. 2008;23 Suppl 1:15–26.CrossRef
12.
Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):460–6.PubMedCrossRef
13.•
Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067–75. Recent estimates of T2D disease burden in youths taking antipsychotics in the US.PubMedCrossRef
14.
Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6):1135–41.PubMedCrossRef
15.•
Nielsen RE, Laursen MF, Vernal DL, Bisgaard C, Jakobsen H, Steinhausen HC, et al. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case–control study. J Am Acad Child Adolesc Psychiatry. 2014;53(9):971–9 e6. Recent estimates of T2D disease burden in youths taking antipsychotics in Denmark.PubMedCrossRef
16.
Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother. 2008;42(9):1316–22.PubMedCrossRef
17.•
Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–63. Describes metabolic profile of a young patient cohort early on in the course of psychiatric disease.PubMedCrossRef
18.
Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, et al. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev. 2014;15(3):202–14.PubMedCrossRef
19.
Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010;18(8):1646–51.CrossRef
20.••
Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends endocrinol Metabolism: TEM. 2014;25(11):593–600. Excellent review of hypothesis and recent findings on antipsychotics and diabetes.CrossRef
21.
Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes, Obesity Metabolism. 2009;11(7):665–79.PubMedCrossRef
22.
Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009;36(4):341–50.PubMedCrossRef
23.••
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–26. Comprehensive review on the topic.CrossRef
24.••
Holt RI, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol. 2015;11(2):79–89. Comprehensive review on the topic.PubMedCrossRef
25.
De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry: J Assoc Eur Psychiatrists. 2011;26(3):144–58.CrossRef
26.•
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4), e94112. Summarizes data on weight gain associated with various antipsychotics.PubMedCentralPubMedCrossRef
27.
Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2–3):225–33.PubMedCentralPubMedCrossRef
28.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–73.PubMedCentralPubMedCrossRef
29.
De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–59.PubMedCrossRef
30.••
Kao AC, Muller DJ. Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics. 2013;14(16):2067–83. Comprehensive review on the topic.PubMedCrossRef
31.•
Shams TA, Muller DJ. Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. Current Psychiatry Reports. 2014;16(10):473. Comprehensive review on the topic.PubMedCrossRef
32.••
Ngai YF, Sabatini P, Nguyen D, Davidson J, Chanoine JP, Devlin AM, et al. Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol. 2014;34(3):359–64. Demonstrates effects of quetiapine on beta cell function in youths.PubMedCrossRef
33.
Manu P, Correll CU, Wampers M, van Winkel R, Yu W, Shiffeldrim D, et al. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone. Schizophr Res. 2013;143(2–3):358–62.PubMedCrossRef
34.
Starrenburg FC, Bogers JP. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry: J Assoc Eur Psychiatrists. 2009;24(3):164–70.CrossRef
35.••
Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62(9):3232–40. Demonstrates weight-independent effects of antipsychotics on insulin resistance.PubMedCentralPubMedCrossRef
36.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.
37.
De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry: J Assoc Eur Psychiatrists. 2009;24(6):412–24.CrossRef
38.
De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry: J Mental Sci. 2011;199(2):99–105.CrossRef
39.
Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, Cg g. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Canadian Acad Child Adolescent Psychiatry. 2011;20(3):218–33.
40.•
Manu P, Correll CU, van Winkel R, Wampers M, De Hert M. Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry. 2012;73(4):460–6. Describes prevalence and clinical characteristics of prediabetes in this patient group.PubMedCrossRef
41.
American Diabetes Association. Standards of Medical Care in Diabetes. 11. Children and adolescents. Diabetes Care. 2015;38(Supplement 1):S70–S6.CrossRef
42.
Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364–82.PubMedCrossRef
43.
44.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.PubMedCrossRef
45.
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.PubMedCrossRef
46.•
Werneke U, Taylor D, Sanders TA. Behavioral interventions for antipsychotic induced appetite changes. Current Psychiatry Reports. 2013;15(3):347. Discusses aspects of behavioral intervention in this patient group.PubMedCentralPubMedCrossRef
47.
Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom AJ, et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75(5):e424–40.PubMedCrossRef
48.••
Green CA, Yarborough BJ, Leo MC, Yarborough MT, Stumbo SP, Janoff SL, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry. 2015;172(1):71–81. Evaluates efficacy of lifestyle intervention in patients with SMI who receive antipsychotics.PubMedCrossRef
49.••
Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368(17):1594–602. Evaluates efficacy of lifestyle intervention in patients with SMI, most of whom receive antipsychotics.PubMedCentralPubMedCrossRef
50.•
Arnoldy R, Curtis J, Samaras K. The effects of antipsychotic switching on diabetes in chronic schizophrenia. Diabet Med. 2014;31(3):e16–9. A case report demonstrating dramatic effects of antipsychotic switching on glucose metabolism.PubMedCrossRef
51.
Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010;12, CD006629.PubMed
52.
Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry: J Assoc Eur Psychiatrists. 2010;25 Suppl 2:S12–21.CrossRef
53.•
Curtis J, Newall H, Myles N, Shiers D, Samaras K. Considering metformin in cardiometabolic protection in psychosis. Acta Psychiatr Scand. 2012;126(4):302–3. Perspectives on the topic.PubMedCrossRef
54.•
Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol. 2012;27(2):69–75. Review of metformin use in adults and pediatric patients with psychiatric illnesses.PubMedCrossRef
55.
Hasnain M, Fredrickson SK, Vieweg WV. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs. J Psychopharmacol. 2011;25(6):715–21.PubMedCrossRef
56.•
Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385–403. Review of use of metformin and other pharmacological agents in adults and pediatric patients with schizophrenia.PubMedCrossRef
57.
Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. 2002;159(4):655–7.PubMedCrossRef
58.
Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072–9.PubMedCrossRef
59.
Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J. 2008;29(8):1130–4.PubMed
60.
Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185–93.PubMedCrossRef
61.
Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22(6):925–7.PubMedCrossRef
62.
Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry: J Mental Sci. 2009;194(6):491–9.CrossRef
63.•
Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125–47. Demonstrates disparities in health care among patients with SMI.PubMedCrossRef
64.
Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med. 2005;165(22):2631–8.PubMedCrossRef
65.••
Shiers D, Curtis J. Cardiometabolic health in young people with psychosis. Lancet Psychiatry. 2014;1(7):492–4. Describes the history and goals of the HeAL initiative.CrossRef
66.••
67.••
Curtis J, Newall HD, Samaras K. The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv Psychiatry. 2012;6(3):347–53. Discusses framework for early cardiometabolic intervention in youths with SMI who receive antipsychotics.PubMedCrossRef
Metadata
Title
Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics
Authors
Pornpoj Pramyothin
Lalita Khaodhiar
Publication date
01-08-2015
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 8/2015
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-015-0623-4

Other articles of this Issue 8/2015

Current Diabetes Reports 8/2015 Go to the issue

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Health Effects of Fructose and Fructose-Containing Caloric Sweeteners: Where Do We Stand 10 Years After the Initial Whistle Blowings?

Psychosocial Aspects (KK Hood and S Jaser, Section Editors)

When Does Personalized Feedback Make A Difference? A Narrative Review of Recent Findings and Their Implications for Promoting Better Diabetes Self-Care

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (E Mayer-Davis and C Shay, Section Editors)

Early-Life Exposure to Substance Abuse and Risk of Type 2 Diabetes in Adulthood

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS)

Psychosocial Aspects (KK Hood and S Jaser, Section Editors)

Practical Strategies to Enhance Executive Functioning and Strengthen Diabetes Management Across the Lifespan

Psychosocial Aspects (KK Hood and S Jaser, Section Editors)

Anxiety in Children and Adolescents With Type 1 Diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits